NCT05699213 is a clinical trial of Lung MRI in Lung Cancer, sponsored by Cedars-Sinai Medical Center.

Who is sponsoring NCT05699213?

NCT05699213 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT05699213?

Interventions in NCT05699213: Lung MRI, Blood Draw.

What condition does NCT05699213 study?

NCT05699213 studies Lung Cancer.

Is NCT05699213 still recruiting?

NCT05699213 is currently recruiting now. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT05699213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

Recruiting now Last updated 30 August 2023

What this trial tests

trial testing Lung MRI in Lung Cancer in 30 participants. Currently enrolling.

Timeline

27 June 2023

Primary endpoint
27 June 2026

27 August 2026

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	30
Start date	27 June 2023
Primary completion	27 June 2026
Estimated completion	27 August 2026
Sites	1 location across United States

Drugs / interventions tested

Lung MRI
Blood Draw — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Cedars-Sinai Medical Center

Who can join

50 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this pilot observational study is to evaluate the accrual and retention rate of a study population from a centralized lung cancer screening program to support MRI and blood-based biomarker research for lung cancer screening.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774

Verify or expand the search:

Other trials of Lung MRI

Trials testing the same drug.

NCT04644471 — Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis · NA · completed
NCT03773991 — Dyspnea Assessment in Hemodialysis Patients · completed
NCT03475264 — MRI of Lung Structure and Function in Preterm Children · terminated

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05699213 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing